Get the Stockscreener App
1.07
0.94%
0.01
After Hours:
1.09
0.02
+1.87%
An 2 Therapeutics Inc stock is traded at $1.07, with a volume of 134.86K.
It is up +0.94% in the last 24 hours and down -5.31% over the past month.
AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease.
See More
Previous Close:
$1.06
Open:
$1.08
24h Volume:
134.86K
Relative Volume:
0.23
Market Cap:
$31.93M
Revenue:
-
Net Income/Loss:
$-64.73M
P/E Ratio:
-0.3821
EPS:
-2.8
Net Cash Flow:
$-53.29M
1W Performance:
+2.88%
1M Performance:
-5.31%
6M Performance:
-67.08%
1Y Performance:
-93.35%
1-Day Range:
$1.06
$1.08
1-Week Range:
$1.03
$1.0867
52-Week Range:
$0.87
$22.22
An 2 Therapeutics Inc Stock (ANTX) Company Profile
Name
An 2 Therapeutics Inc
Sector
Industry
Phone
(650) 331-9090
Address
1800 EL CAMINO REAL, SUITE D, MENLO PARK
An 2 Therapeutics Inc Stock (ANTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-18-22 | Resumed | Oppenheimer | Outperform |
An 2 Therapeutics Inc Stock (ANTX) Latest News
Araris Doubles Down With Dual-payload ADC - BioProcess Online
Ildikó Enyedi working on her new feature, Silent Friend - Cineuropa
Boss Brown calls on Ayr players to step up after losing top scorer for season - Ayr Advertiser
Black Diamond Therapeutics to Host Webcast Presentation of - GlobeNewswire
Black Diamond Therapeutics to Host Webcast Presentation of Initial Phase 2 BDTX-1535 Data in Patients With Recurrent EGFRm NSCLC - Yahoo Finance
Scott Brown admits Anton Dowds injury is huge blow for Ayr United as he challenges others to step up - Daily Record
Adicet Bio shares hold neutral rating amid positive study data By Investing.com - Investing.com South Africa
Adicet Bio reports promising ADI-001 therapy data - Investing.com
Australia's Amplia Therapeutics rises as US FDA fast-tracks cancer drug - XM
Applied Therapeutics: AdCom Decision Takes Govorestat Approval A Step Closer (NASDAQ:APLT) - Seeking Alpha
Edgewise Therapeutics Announces Positive Top-Line Data from Phase 1 Trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM) - Business Wire
Agatha All Along Episode 2 Cast & Characters Guide (Photos) - The Direct
Plus Therapeutics Showcases New Interim ReSPECT-GBM Phase 2 - GlobeNewswire
VERV CLASS ACTION: Verve Therapeutics, Inc. Stockholders - GlobeNewswire
IVIEW Therapeutics Inc. Completes Patient Recruitment for Phase 1/2 Trial of IVW-1001 Ophthalmic Eyelid Wipe in Dry Eye Disease Patients - PR Newswire
IVIEW Therapeutics Inc. Completes Patient Recruitment for Phase 1/2 Trial of IVW-1001 Ophthalmic Eyelid Wipe in Dry Eye Disease Patients - Yahoo Finance
Nanoscope Therapeutics Announces End-of-Phase 2 Meeting with U.S. FDA and Plan to Initiate a Phase 3 Clinical Trial of MCO-010 to Treat Stargardt Macular Degeneration - PR Newswire
Intellia Therapeutics to Present Data from the Phase 2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the 2024 ACAAI Annual Scientific Meeting - GlobeNewswire
Intellia Therapeutics to Present Data from the Phase 2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the 2024 ACAAI Annual Scientific Meeting - Yahoo Finance
Allarity Therapeutics Takes Decisive Step Toward Regaining Nasdaq Compliance with Nasdaq Listing Rule 5550(a)(2) - GlobeNewswire
Allarity Therapeutics Takes Decisive Step Toward Regaining Nasdaq Compliance with Nasdaq Listing Rule 5550(a)(2) - Yahoo Finance
Keros Therapeutics Announces Update on Enrollment in the Phase 2 TROPOS Trial - GlobeNewswire
Keros Therapeutics Announces Update on Enrollment in the Phase 2 TROPOS Trial - Yahoo Finance
Dyne Therapeutics Announces New Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented Dystrophin Expression and Functional Improvement in Multiple Cohorts - Yahoo Finance
Soleno Therapeutics: 2 New Catalysts To Bring Forth Change For PWS Patients (SLNO) - Seeking Alpha
Innovo Therapeutics Inc. Announces Phase 2 Clinical Results Demonstrating the Innovative Efficacy of INV-001 for the Treatment of Post-thyroidectomy Scars - Winchester Herald Chronicle
Director J Singleton Sells 5,700 Shares of Viking Therapeutics Inc (VKTX) - Yahoo Finance
Cognition Therapeutics Publishes EEG Findings from Phase 2 SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease - Yahoo Finance
Innovo Therapeutics Inc. Announces Phase 2 Clinical Results Demonstrating the Innovative Efficacy of INV-001 for the Treatment of Post-thyroidectomy Scars - Manchestertimes
Innovo Therapeutics Inc. Announces Phase 2 Clinical Results Demonstrating the Innovative Efficacy of INV-001 for the Treatment of Post-thyroidectomy Scars - Business Wire
iTeos Therapeutics Announces Late-Breaking Oral - GlobeNewswire
iTeos Therapeutics Announces Late-Breaking Oral Presentation of Phase 2 GALAXIES Lung-201 Interim Data at the European Society for Medical Oncology Congress 2024 - Yahoo Finance
Scorpion Therapeutics to Present STX-478 Initial Phase 1/2 Data at ESMO Congress 2024 - Business Wire
Why Is Viking Therapeutics, Inc. (VKTX) the Best Diabetes Stock to Buy Now? - Yahoo Finance
Are Medical Stocks Lagging Acrivon Therapeutics, Inc. (ACRV) This Year? - Yahoo Finance
Tempest Announces Successful End-of-Phase 2 Meeting with - GlobeNewswire
Viracta Therapeutics Announces Positive Data from the Phase - GlobeNewswire
AN2 Therapeutics Provides Update on EBO-301 Phase 2/3 Study Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium Complex (MAC) Lung Disease - Business Wire
Intellia Therapeutics Announces Second Quarter 2024 Financial Results and Highlights Recent Company Progress - GlobeNewswire
Travere Therapeutics, Inc. (TVTX) Q2 2024 Earnings Call Transcript - Seeking Alpha
OVID Investors Have Opportunity to Join Ovid Therapeutics Inc. Fraud Investigation with the Schall Law Firm - Morningstar
Intellia Therapeutics Receives Authorization to Initiate Phase 1/2 Clinical Trial of NTLA-3001 for the Treatment of Alpha-1 Antitrypsin Deficiency - GlobeNewswire
Cognition Therapeutics, Inc?s Proof-of-Concept Phase 2 SHINE Trial Demonstrates Consistent Improvement in Cognitive Outcomes with Once-Daily Oral CT1812 in Mild-to-Moderate Alzheimer?s Patients - Marketscreener.com
Cognition Therapeutics’ Proof-of-Concept Phase 2 SHINE - GlobeNewswire
Cognition Therapeutics to Host Investor Webcast to Discuss - GlobeNewswire
CytoMed Therapeutics (NASDAQ:GDTC) Trading Down 2% - Defense World
Viridian Therapeutics Announces Completion of THRIVE-2 Enrollment for VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED) - Yahoo Finance
Viking Therapeutics, Inc. (VKTX) Q2 2024 Earnings Call Transcript - Seeking Alpha
Viking Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update - PR Newswire
Galectin Therapeutics And 2 Other Stocks Under $5 Insiders Are Buying - Benzinga
Sage Therapeutics and Biogen Announce Topline Results from Phase 2 KINETIC 2 Study of SAGE-324 (BIIB124) for the Treatment of Essential Tremor - Biogen | Investor Relations
An 2 Therapeutics Inc Stock (ANTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):